Pfizer-BioNTech's COVID-19 Booster Study Shows Robust Efficacy

$Pfizer(PFE.US)$ and $BioNTech(BNTX.US)$ announced topline results from a Phase 3 trial evaluating the efficacy and safety of a 30-µg booster dose of its COVID-19 vaccine.Data from a large study showed that the booster dose restored efficacy to 95.6% against the virus, including the Delta variant.
The companies said the trial was not peer-reviewed, tested 10,000 participants aged 16 and older, and found that the booster shot had a favorable safety profile.